The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Vasomotor Symptoms Market has been comprehensively analyzed in IMARC's new report titled "Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Vasomotor symptoms are temperature dysfunctions that occur due to changes in gonadal hormones in females. These symptoms occur due to the constriction or dilation of blood vessels. These symptoms can also be referred to as menopausal symptoms, for which women seek treatment during menopause most often. At around the age of 40, estrogen and progesterone levels start to reduce in females. Therefore, as the females get older, a female may experience vasomotor symptoms. These hormonal fluctuations affect the mechanisms that control blood pressure and temperature control, and females may experience different symptoms. Vasomotor symptoms include hot flashes, night sweats, heart palpitations, and changes in blood pressure. Hormone therapy is the most effective treatment for vasomotor symptoms and other menopausal symptoms. Estrogens are known as potent neuromodulators of several neuronal circuits throughout the central nervous system. Changing estrogen levels during menopause may impact multiple components in maintaining temperature homeostasis. Similarly, for the drug discovery process, understanding the cause of thermoregulatory dysfunction and mechanisms involved in temperature regulation help specialists to introduce effective drugs.
The rising prevalence of menopausal and post-menopausal symptoms owing to the adoption of unhealthy eating habits and sedentary lifestyles is primarily driving the vasomotor symptoms market. In addition to this, the ongoing development of several treatment options that target the brain's thermostat to reduce the incidence of vasomotor symptoms, such as hot flashes, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of non-hormonal alternatives, such as selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors, among patients with a history of breast cancer is also bolstering the market growth. Apart from this, the escalating demand for cognitive behavior therapy for treating complications associated with vasomotor symptoms, such as sleep disturbances and low-productivity levels in professional environments, is further creating a positive outlook for the market. This nonpharmacologic treatment aids in modifying dysfunctional emotions, behaviors, and thoughts that enhance personal coping strategies. Additionally, several governing bodies, along with non-governmental organizations (NGOs), are supporting various health education campaigns to address the stigma and associated silence pertaining to symptoms of menopause. This, in turn, is also propelling the adoption of drugs and medications for the treatment of vasomotor symptoms. Apart from this, the introduction of various innovative approaches for treating distressing vasomotor symptoms with the lowest effective dose in the shortest duration is expected to drive the vasomotor symptoms market in the coming years.
IMARC Group's new report "Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Vasomotor Symptoms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Vasomotor Symptoms market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Vasomotor Symptoms across the seven major markets. According to the report the United States has the largest patient pool for Vasomotor Symptoms and also represents the largest market for Vasomotor Symptoms treatment. Furthermore, the current Vasomotor Symptoms treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Vasomotor Symptoms market in any manner.
Time Period of the Study
This report also provides a detailed analysis of the current Vasomotor Symptoms marketed drugs and late-stage pipeline drugs.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at